ConductScience.org, home

Paper9537252

Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines.

Pulaski BA and 1 other. Cancer Res, 1998. Cited by 344 papers, by iCite.

Cite this record

ConductScience Library. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Papers, record 9537252. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9537252

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines.
PubMed
Journal
Cancer Res
PubMed
Year
1998
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
344
iCite
Relative citation ratio, by iCite
6.58
iCite
Revised in PubMed
2022-03-30
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Pulaski BAB A
2Ostrand-Rosenberg SS

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
B7-1 AntigenMajor topic
Cancer VaccinesMajor topic
Histocompatibility Antigens Class IIMajor topic
Immunotherapy, ActiveMajor topic
Mammary Neoplasms, ExperimentalMajor topic
Neoplasm MetastasisMajor topic
Animals
Antimetabolites, Antineoplastic
Cell Division
Disease Models, Animal
Drug Resistance, Neoplasm
Female
Mice
Mice, Inbred BALB C
T-Lymphocytes
Thioguanine
Transfection

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
R01 CA52527NCI NIH HHSUnited StatesR01CA052527PubMed and NIH

Source NIH RePORTER

Download CSV of grants

Cited by211

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 344 citations.

PMIDTitleJournalYearIn PapersSource
42595355Turning off methylglyoxal stress: an alternative approach to inhibit MDSC expansion and metastasis in triple-negative breast cancer.J Immunother Cancer2026https://conductscience.org/library/papers/42595355PubMed
42428078The MHCII Immune Activation Score predicts risk of recurrence and benefit of taxanes in Basallike and HER2-enriched breast cancer.medRxiv2026https://conductscience.org/library/papers/42428078PubMed
41639695ISG15-driven immune modulation and tumor progression in breast cancer metastasis: insights from single-cell and spatial transcriptomics.BMC Med2026https://conductscience.org/library/papers/41639695PubMed
41480638IGF1R-targeted delivery of a bridged nucleic acid oligonucleotide-peptide conjugate for microRNA-21 inhibition in triple-negative breast cancer.NAR Cancer2025https://conductscience.org/library/papers/41480638PubMed
41458569A Cell Membrane-Coated Gold Nanoparticle-Based Drug Delivery System for Enhanced Antitumor Therapy in Breast Cancer.Int J Nanomedicine2025https://conductscience.org/library/papers/41458569PubMed
41424840Nanoparticle retention enables non-invasive detection of metastases by magnetic particle imaging in murine breast cancer models.Theranostics2026https://conductscience.org/library/papers/41424840PubMed
40927638Targeting Tumor-Associated Hypoxia with Bioreductively Activatable Prodrug Conjugates Derived from Dihydronaphthalene, Benzosuberene, and Indole-based Inhibitors of Tubulin Polymerization.RSC Med Chem2025https://conductscience.org/library/papers/40927638PubMed
40836337CDK4/6 inhibitors synergize with radiotherapy to prime the tumor microenvironment and enhance the antitumor effect of anti-PD-L1 immunotherapy in triple-negative breast cancer.J Biomed Sci2025https://conductscience.org/library/papers/40836337PubMed
40410902Characterization of extracellular vesicle-associated DNA and proteins derived from organotropic metastatic breast cancer cells.J Exp Clin Cancer Res2025https://conductscience.org/library/papers/40410902PubMed
40389728
Mitigating radioresistance mechanisms by polymer-lipid manganese dioxide nanoparticles enhances immunogenic cell death and antitumor immune response to facilitate abscopal effect in breast tumor models.
Drug Deliv Transl Res2026https://conductscience.org/library/papers/40389728PubMed
40304334Comparative Glycoproteomic Analysis of Mouse 4T1 Breast Cancer Model.Curr Med Chem2025https://conductscience.org/library/papers/40304334PubMed
40103600Cancer metastasis to the bone: Mechanisms and animal models (Review).Oncol Lett2025https://conductscience.org/library/papers/40103600PubMed
40071025Breast cancer preclinical models: a vital resource for comprehending disease mechanisms and therapeutic development.EXCLI J2025https://conductscience.org/library/papers/40071025PubMed
39629131Ultrafast power doppler ultrasound enables longitudinal tracking of vascular changes that correlate with immune response after radiotherapy.Theranostics2024https://conductscience.org/library/papers/39629131PubMed
39488625Screening and validating the optimal panel of housekeeping genes for 4T1 breast carcinoma and metastasis studies in mice.Sci Rep2024https://conductscience.org/library/papers/39488625PubMed
39189475mRNA-Lipid Nanoparticle-Mediated Restoration of PTPN14 Exhibits Antitumor Effects by Overcoming Anoikis Resistance in Triple-Negative Breast Cancer.Adv Sci (Weinh)2024https://conductscience.org/library/papers/39189475PubMed
39164434Interleukin 4 and cancer resistance in glioblastoma multiforme.Neurosurg Rev2024https://conductscience.org/library/papers/39164434PubMed
39012440State of the Art Modelling of the Breast Cancer Metastatic Microenvironment: Where Are We?J Mammary Gland Biol Neoplasia2024https://conductscience.org/library/papers/39012440PubMed
38543072Dual Role of Alchemilla vulgaris L. Extract in Breast Cancer Regression: Reestablishment of Effective Immune Response.Pharmaceuticals (Basel)2024https://conductscience.org/library/papers/38543072PubMed
38380618Decreased Lung Metastasis in Triple Negative Breast Cancer Following Locally Delivered Supratherapeutic Paclitaxel-Loaded Polyglycerol Carbonate Nanoparticle Therapy.Biomacromolecules2024https://conductscience.org/library/papers/38380618PubMed

See all 211 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/9537252

GET https://conductscience.org/api/papers/v1/9537252/cited_by?page=2